Reviews/Ssris and Snris/SSRIs and SNRIs cause sexual dysfunction in 30-40% of treated patients
· SS-SAF-01 · v2
The corpus shows clearly that these antidepressants can cause sexual problems: a controlled study in healthy men found subjective sexual dysfunction rose under paroxetine [1], and a large survey of treated patients found such problems to be very common [8]. What it does not show is the specific claim that 30 to 40 out of every 100 treated patients are affected. The one large survey that could speak to overall prevalence [8] deliberately left out the patients with the most severe, across-the-board dysfunction, and it reports very high rates within narrow phases of the sexual response, not a 30-40% whole-patient rate. A separate study [14] found that many depressed patients already had reduced sexual interest before any medication, so some of what is seen cannot be pinned on the drug. The exact 30-40% band appears only in literature reviews [11] that the panel set aside because they are not primary studies.
A placebo-controlled within-subject study in 18 healthy males found that subjective sexual dysfunction increased under paroxetine relative to placebo or bupropion [1], supporting a causal direction. A cross-sectional survey of a 3114-patient SSRI/SNRI subsample found that 95.6% of women and 97.9% of men showed impairment in at least one phase of sexual functioning [8], establishing that dysfunction is highly common among treated patients. However, that subsample was explicitly restricted to patients who did not meet criteria for global sexual dysfunction [8], so it does not provide a whole-patient denominator. A study of 134 untreated major-depression patients found over 40% of men and 50% of women with decreased sexual interest and reduced arousal in 40-50% before any treatment [14], showing baseline dysfunction attributable to the illness itself. The contested point: The division is between well-attested qualitative causation and the unverified specific 30-40% band: no included primary study reports that rate, and the only primary prevalence-relevant study [8] both excludes the relevant denominator and reports phase-specific impairment far above the claimed range (71-97%). The high baseline dysfunction in untreated patients [14] further contests any clean attribution of a fixed treated-patient prevalence to the drugs.
All 18 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Ssris and Snris, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The specific 30-40% figure appears nowhere in the surviving primary research; it exists only in reviews ([11] states '30% and 60%') that were excluded by the study-type filter, so no admissible primary source confirms the quantitative band.
[8], the only global-prevalence-relevant primary study, used a subsample explicitly selected to exclude patients meeting criteria for global sexual dysfunction, and reports phase-specific impairment at 70-97% — it neither provides a valid denominator for a 30-40% global rate nor supports that specific figure.
Where it remains uncertain. The one prevalence-relevant primary study [8] excluded patients with global dysfunction and reported phase-specific rates of 95.6% and 97.9%, while untreated patients already showed 40-50% baseline dysfunction [14], so neither supports a 30-40% treated-patient band.
Aleatory
Sexual dysfunction risk varies across patients and agents, so a single prevalence figure masks real spread; [8] reports differing phase-specific rates by sex and [1] isolates paroxetine.
Epistemic
No included primary study reports a global 30-40% prevalence; the figure exists only in reviews ([11], '30% and 60%') excluded by the study-type filter.
Inferential
[8] restricted its subsample to patients who did not meet criteria for global sexual dysfunction and reports phase-specific rates of 95.6% and 97.9%, which cannot be read as a whole-patient 30-40% rate.
The load-bearing papers from a corpus of 18, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Controlled within-subject evidence that an SSRI causes sexual dysfunction (direction of effect), though in 18 healthy males with no prevalence rate.
“Under paroxetine, ratings of subjective sexual dysfunction increased compared with placebo or bupropion.”
Panel auditInternal validity: medium · scope of inference: Acute neural and subjective sexual effects of paroxetine in healthy males, not SD incidence in treated patients.Key limitations: tiny sample · healthy not depressed · no prevalence endpoint · 7-day exposure
Primary cross-sectional data in SSRI/SNRI-treated patients, but in a subsample selected to exclude global sexual dysfunction and reporting far higher phase-specific rates than the claimed 30-40%.
“Among this sub-sample, 95.6% of women and 97.9% of men exhibited impairment in at least one phase of sexual functioning.”
Panel auditInternal validity: medium · scope of inference: Phase-specific sexual impairment among SSRI/SNRI patients who lack clinically significant global dysfunction.Key limitations: selected subgroup · phase-specific not global rate · no baseline/control
Documents high baseline sexual dysfunction BEFORE antidepressant treatment, a confound that prevents attributing a specific prevalence to the drugs alone.
“Over 40% of men and 50% of women reported decreased sexual interest.”
Panel auditInternal validity: low · scope of inference: Baseline prevalence of sexual dysfunction in major depression before any antidepressant.Key limitations: pre-treatment only · no control group · confounds drug vs disease
3 of 18 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Qualitative causation is strong, but no included primary study verifies the specific 30-40% prevalence and a baseline confound is unaddressed, so the claim as worded cannot be scored above Uncertain.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Denominator-based global prevalence in treated patients. The claim is a point-estimate prevalence, yet no included primary study provides an unselected treated-patient denominator for global sexual dysfunction; [8]'s subsample excluded global-dysfunction cases. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective cohort of unselected SSRI/SNRI-treated patients using a validated scale that captures global dysfunction, reporting the proportion affected against the full denominator.
Open question: What proportion of unselected SSRI/SNRI-treated patients develop treatment-emergent global sexual dysfunction? Why it is still open: No included primary study reports a global prevalence denominator; [8] excluded global-dysfunction cases by design and the 30-40% figure appears only in excluded reviews [11].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19